Vaccine patentsBulk PDF Downloads |
This page is updated frequently with new Vaccine-related patent applications.
 Cancer markers and methods of use thereofThe present disclosure relates to methods and compositions which can modulate the globoseries glycosphingolipid synthesis. Particularly, the present disclosure is directed to glycoenzyme inhibitor compound and compositions and methods of use thereof that can modulate the synthesis of globoseries glycosphingolipid ssea-3/ssea-4/globoh in the biosynthetic pathway; particularly, the glycoenzyme inhibitors target the alpha-4galt; beta-4galnact-i; or beta-3galt-v enzymes in the globoseries synthetic pathway. Academia Sinica |
 Soluble hiv-1 envelope glycoprotein trimersThe present application relates to novel hiv-1 envelope glycoproteins which may be utilized as an hiv-1 vaccine immunogens, antigens for crystallization and for the identification of broad neutralizing antibodies. The present invention encompasses the preparation and purification of immunogenic compositions which are formulated into the vaccines of the present invention.. The Scripps Research Institute |
 Cdca1 epitope peptides and vaccines containing the samePeptide vaccines against cancer are described herein. In particular, the present invention describes epitope peptides derived from cdca1 that elicit ctls. Oncotherapy Science, Inc. |
 Nucleic acids for treatment of allergiesThe present invention provides dna vaccines for the treatment of allergies. The vaccines comprise the coding sequence for one or more allergenic epitopes, and preferably the full protein sequence, of the allergenic protein from which the epitope(s) is derived, fused inframe with the lumenal domain of the lysosomal associated membrane protein (lamp) and the targeting sequence of lamp. Immunomic Therapeutics, Inc. |
 Approach to produce hiv-1 gp140 envelope protein trimersProvided herein are hiv vaccines that encompasses recombinant trimers that mimic native hiv-1 envelope trimers. Also provided are methods of administering to a subject in need thereof an hiv vaccine provided herein to elicit antibodies against a recombinant trimer in the subject. The Catholic University Of America |
 Tetanus toxoid and ccl3 improve dc vaccinesPre-conditioning a vaccine site with a potent recall antigen such as tetanus/diphtheria (td) toxoid can significantly improve the lymph node homing and efficacy of tumor antigen-specific dc vaccines. Patients given td had enhanced dc migration bilaterally and significantly improved survival. Duke University |
 Use of microrna precursors as drugs for inducing cd34-positive adult stem cell expansionThis invention generally relates to a composition and its production method useful for developing drugs/vaccines and/or therapies against a variety of degenerative diseases in humans. Particularly, the present invention teaches the essential steps of production and purification processes necessary for producing small hairpin-like rna (shrna) compositions, such as microrna precursors (pre-mirna) and short interfering rnas (sirna), which are useful for treating human ageing related diseases, such as, but not limited, alzheimer's diseases, parkinson's diseases, osteoporosis, diabetes, and cancers. |
 Nucleic acids and proteins from streptococcus groups a and bThe invention provides proteins from group b streptococcus (streptococcus agalactiae) and group a streptococcus (streptococcus pyogenes), including amino acid sequences and the corresponding nucleotide sequences. Data are given to show that the proteins are useful antigens for vaccines, immunogenic compositions, and/or diagnostics. J. Craig Venter Institute, Inc. |
 Composition for preventing mycoplasma spp. infectionThe present invention provides proteins that are suitable to be used as the active ingredient in subunit vaccine against mycoplasma spp. The present invention also provides a subunit vaccine made therefrom. Agricultural Technology Research Institute |
 Novel adenovirus isolated from titi monkeysProvided is a titi monkey adenovirus (tmadv) that can infect both human and non-human primates. Further provided are nucleic acid sequences, proteins, expression vectors and host cells, anti-tmadv antibodies, vaccines, compositions, methods of detecting tmadv, methods for assaying for anti-tmadv compounds, and methods for treating or preventing a tmadv infection.. The Regents Of The University Of California |
The present invention provides for microneedle arrays and related systems and methods. Particularly, microneedle arrays that are configured to deliver active agents, including nucleic acids and vaccines, are provided. Transderm, Inc. |
The invention improves tdap vaccines by including a tlr agonist in them. This agonist can provide stronger protection, longer-lasting protection, and/or can reduce the amount of antigen which is required to achieve a particular immune response.. Glaxosmithkline Biologicals Sa |
The invention relates to a conjugate based on vi polysaccharide which is fragmented and a carrier protein, to compositions comprising said conjugate and to methods for making said conjugates and compositions.. . Glaxosmithkline Biologicals S.a. |
Live attenuated infectious laryngotracheitis virus (iltv) vaccines and preparation thereof This disclosure describes a modified live infectious laryngotracheitis virus (iltv) developed from a strain of iltv grown at a reduced incubation temperature, vaccines that include the modified live iltv, methods for producing the live modified iltv, and methods that include administering the modified iltv to a subject.. . University Of Delaware |
A method for preventing, treating or reducing the effects of influenza infection in a subject by administering an influenza vaccine to the skin of the subject. The administration can be intradermal or by microneedle patch. Sporos Therapeutics, Llc |
Ctl peptide epitopes and antigen-specific t cells, methods for their discovery, and uses thereof The present invention relates to ctl peptide epitopes, high-throughput methods for their identification, and their uses. In particular, the present invention relates to peptide epitopes for cancer immunotherapy and hepatitis c virus vaccines. Oslo Universitetssykehus Hf |
Marker system, in particular for baculovirus-expressed subunit antigens The present invention belongs to the field of compliance markers and marker vaccines which allow for the differentiation between infected and vaccinated individuals. In particular, it relates to a method of determining whether an individual has received an immunogenic composition comprising a recombinant protein produced by a baculovirus expression system in cultured insect cells.. Boehringer Ingelheim Vetmedica, Inc. |
Duck embryonic derived stem cell lines for the production of viral vaccines The present invention relates to the development and manufacturing of viral vaccines. In particular, the invention relates to the field of industrial production of viral vectors and vaccines, more in particular to the use of avian embryonic stem cells, preferably the ebx® cell line derived from duck embryonic stem cells, for the production of viral vectors and viruses. Valneva |
The present invention relates to peptides comprising at least one cd4+ t epitope, which is immunodominant in vitro, of the cyclin b1 tumor antigen, said peptides being capable of stimulating a specific human cd4+ t lymphocyte response in subjects who have varied hla ii molecules, and to the use of these peptides as a cancer vaccine and as a reagent for the diagnosis of cancer or the immunomonitoring of the cellular response against cyclin b1 during cancer or during an anticancer treatment.. . Commissariat A L'energie Atomique Et Aux Energies Alternatives |
Order a batch download of a huge number of patent PDFs.
Bulk PDF Downloads
This is a premium service.
|
Hiv-1 antigens with discrete conformational forms on the v1/v2 domain and methods of use thereof The present invention relates to a novel composition of hiv-1 env proteins that contain structurally and immunologically distinct vi/v2 domains. Methods of isolating such proteins, and methods of using such proteins as immunogens, therapeutic agents, vaccines, and test compounds for use in identifying a hiv antiviral are also provided.. Rutgers, The State University Of New Jersey |
The present invention provides compositions and methods of use comprising a chimeric dengue virus e glycoprotein comprising a dengue virus e glycoprotein backbone, which comprises amino acid substitutions that introduce an epitope that is recognized by an antibody from a dengue virus serotype that is different from the dengue virus serotype of the dengue virus e glycoprotein backbone.. . The University Of North Carolina At Chapel Hill |
A composition includes at least one mineral oil, a surfactant having a hydrophilic property characterised by an hlb value equal to 12 and a divalent inorganic salt intended to be used as an adjuvant in a vaccine composition for the in ovo vaccination of avian species wherein the composition is an oil-in-water emulsion or microemulsion.. . Societe D'exploitation De Produits Pour Les Industries Chimiques Seppic |
This invention generally relates to cationic oil-in-water emulsions that can be used to deliver negatively charged molecules, such as an rna molecule. The emulsion particles comprise an oil core and a cationic lipid. Novartis Ag |
The present invention relates to monovalent influenza vaccine formulations and vaccination regimes for immunising against influenza disease, their use in medicine, in particular their use in augmenting immune responses to various antigens, and to methods of preparation. In particular, the invention relates to monovalent influenza immunogenic compositions comprising an influenza antigen or antigenic preparation thereof from an influenza virus strain being associated with a pandemic outbreak or having the potential to be associated with a pandemic outbreak, in combination with an oil-in-water emulsion adjuvant comprising a metabolisable oil, a sterol and/or a tocopherol such as alpha tocopherol, and an emulsifying agent.. Glaxosmithkline Biologicals Sa |
Decreasing potential iatrogenic risks associated with influenza vaccines Influenza viruses for use in preparing human vaccines have traditionally been grown on embryonated hen eggs, although more modern techniques grow the virus in mammalian cell culture e.g. On vero, mdck or per.c6 cell lines. Novartis Ag |
Method for increasing etec cs6 antigen presentation on cell surface and products obtainable thereof A method for increasing the presentation of etec cs6 antigen on cell surface, comprising the step of contacting cells expressing said antigen with an aqueous solution comprising 0.6-2.2 percent phenol by weight, such that the presentation of said antigen is increased by at least 100%. A method for the manufacture of a killed whole cell vaccine for immunization against cs6-expressing etc. Scandinavian Biopharma Holding Ab |
Thermostable respiratory synctial virus (rsv) vaccine compositions Methods for improving the drying yield and stability of rsv vaccines comprising a highly thermolabile enveloped live virus and/or one or more rsv protein subunits, are described. Methods for rapid drying of rsv formulations containing between 17.5% and 60% w/w of a non-polymeric sugar and using either conduction or radiation dominant drying mechanisms, are disclosed. Merck Sharp & Dohme Corp. |
Schmallenberg virus (sbv) vaccine, methods of production, and uses thereof The present invention relates to the field of vaccines and medicaments for the prophylaxis and treatment of infectious diseases in ruminants. In particular, it relates to inactivated schmallenberg virus (sbv) useful as vaccine or medicament for preventing or treating viremia, the transmission and clinical symptoms, in particular malformations in newborn ruminants such as cattle, sheep and goats, induced by sbv.. Boehringer Ingelheim Vetmedica Gmbh |
Compositions and methods for detecting, treating, and protecting against fusobacterium infection The present invention relates to protecting against, treating, and detecting fusobacteria infections. Compositions and methods derived from nucleic acid and protein sequences of a 40 kda adhesin protein are provided to protect against, treat, and detect fusobacteria infections in a subject. Kansas State University Research Foundation |
Fusion proteins and combination vaccines comprising haemophilus influenzae protein e and pilin a The present invention relates to compositions comprising haemophilus influenzae protein e and pilin a. More particularly, the present application relates to fusion proteins and immunogenic compositions comprising protein e and pila, vaccines comprising such immunogenic compositions and therapeutic uses of the same.. Glaxosmithkline Biologicals S.a. |
Esters of short chains fatty acids for use in the treatment of immunogenic disorders The present invention relates to short chain fatty acids (scfa) for use in transmucosal administration to a subject for the prevention, attenuation or treatment of a disease or disorder associated with a compromised th1 immune response and/or an unwanted th2 or th2-like immune response by modulating a th2 immune response towards a th1 immune response, particularly for the treatment, prevention and/or amelioration of viral infections and as an adjuvant for promoting the efficiency of vaccines and/or prevention of allergic diseases or disorders.. . Proponent Biotech Gmbh |
Vaccine comprising streptococcus pneumoniae capsular polysaccharide conjugates The present invention discloses an immunogenic composition comprising s. Pneumoniae capsular saccharide conjugates from serotypes 19a and 19f wherein 19a is conjugated to a first bacterial toxoid and 19f is conjugated to a second bacterial toxoid. Glaxosmithkline Biologicals S.a. |
The invention relates to a cmv strain comprising interferon bets (ifnb) useful in immuno-stimulatory compositions and vaccines. . The University Of Sydney |
The invention features stabilized human immunodeficiency virus (h iv) clade c envelope (env) trimers. The invention also features vaccines, nucleic acids, and vectors to deliver and/or facilitate production of the stabilized hiv clade c env trimers. Beth Israel Deaconess Medical Center, Inc. |
The present invention discloses the construction of dengue virus subgenomic replicons containing large deletions in the structural region (c-prem-e) of the genome, which replicons are useful as vaccines to protect against dengue virus infection.. . The United States Of America, As Represented By The Secretary, Department Of Health & Human Servic |
The present invention provides attenuated m. Haemolitica strains that elicit an immune response in animal against m. The United States Of America, As Represented By The Secretary Of Agriculture |
This invention provides novel carbonic anhydrase (caix) nucleic acid and peptide sequences, as well as related methods and compositions, including anti-cancer immunogenic agent(s) (e.g. Vaccines and chimeric molecules) that elicit an immune response specifically directed against cancer cells expressing a caix antigenic marker. The Regents Of The University Of California |
The present invention relates to the field of biotechnology and genetic engineering, and particularly to the expression of recombinant peptides. The inoculation thereof in cattle results in the production of an immune response capable of adversely affecting rhipicephalus microplus ticks, which feed on the inoculated cattle, decreasing the number and reproductive capacity of this tick species. Patsos Endustria E Comercio De Produtos BiotecnolÓgicos Ltda |
Nucleic acid molecules and compositions comprising: a nucleic acid sequence that encodes il-12 p35 subunit or a functional fragment thereof and/or a nucleic acid sequence that encodes il12 p40 subunit or a functional fragment thereof, are disclosed. The nucleic acid molecules and compositions further comprising a nucleic acid sequence that encodes an immunogen are also disclosed. The Trustees Of The University Of Pennsylvania |
Order a batch download of a huge number of patent PDFs.
Bulk PDF Downloads
This is a premium service.
|
Disclosed herein is a vaccine comprising an antigen and il-33. Also disclosed herein is a method for increasing an immune response in a subject in need thereof. Inovio Pharmaceuticals, Inc. |
Therapies, vaccines, and predictive methods for middle east respiratory syndrome virus (mers cov) The present invention provides an isolated or synthesized protein fragment or peptide comprising at least one peptide sequence that is at least 50% homologous with at least one replikin peptide sequence identified in a mers cov. The at least one peptide sequence may be at least 80% homologous with at least one replikin peptide sequence identified in a mers cov. |
Influenza vaccines include hemagglutinin from at least one influenza a virus strain and at least one influenza b virus strain. They also include an oil-in-water emulsion adjuvant with submicron oil droplets, comprising squalene. Seqirus Uk Limited |
The present invention refers to a method for the production of live attenuated bacterial strains, suitable as vaccine candidates, comprising the steps of: a. Providing a bacterial strain capable of expressing glutamate racemase and possibly d-amino acid transaminase and comprising a peptidoglycan cell wail, and b. FundaciÓn Profesor Novoa Santos |
The present disclosure provides methods and composition including vaccines, monoclonal antibodies, polyclonal antibodies, chimeric molecule of an extracellular fibrinogen binding protein (efb) and targeted agent delivery pharmaceutical composition comprising at least a portion of a modified n-terminus region, at least a portion of a modified c-terminus region, or both, wherein the modified extracellular fibrinogen binding protein results in inhibiting the fibrinogen binding, c3 binding, or both or administering to a subject a pharmacologically effective amount of a vaccine in a pharmaceutically acceptable excipient, comprising a modified extracellular fibrinogen binding protein comprising at least a portion of a modified n-terminus region, at least a portion of a modified c-terminus region, or both, wherein the modified extracellular fibrinogen binding protein results in not shielding the staphylococcus bacterium from recognition by a phagocytic receptor.. . University Medical Center Utrecht, The Netherlands |
Process for stabilizing an adjuvant containing vaccine composition The present invention relates to a process for stabilizing an adjuvant containing vaccine composition, an adjuvanted vaccine composition in dry form and in particular a process for stabilizing an influenza vaccine composition, particularly an adjuvanted influenza vaccine composition in dry form.. . Sanofi Pasteur Sa |
Self-contained device and system to produce ex-vivo autologous whole cell tumor vaccines The invention disclosed herein aims to standardize and simplify the process of preparing ex-vivo autologous whole tumor cell vaccines. The present invention is a robust, stand-alone device and system for preparing autologous tumor cell vaccines in a completely self-contained sterile environment, and in a shortened time. |
This document provides methods and materials for producing immune responses against hepatitis b viruses. For example, polypeptides, nucleic acid molecules encoding such polypeptides, virus-like particles containing such polypeptides, vaccine preparations containing one or more polypeptides provided herein, vaccine preparations containing one or more nucleic acid molecules provided herein, vaccine preparations containing one or more virus-like particles provided herein, and methods for inducing immune responses against hepatitis b viruses within mammals (e.g., humans) are provided.. Altravax, Inc. |
Described herein is a recombinant respiratory syncytial virus (rsv) having an attenuated phenotype. In one embodiment, recombinant rsv includes an m2-2 protein with a mutation that renders the m2-2 protein inactive or prevents expression of the m2-2 protein. Medimmune, Llc |
Disclosed herein are compositions and methods related to mutant viruses, and in particular, mutant influenza viruses. The mutant viruses disclosed herein include a mutant m2 sequence, and are useful in immunogenic compositions, e.g., as vaccines. Flugen, Inc. |
Disclosed herein are compositions and methods related to mutant viruses, and in particular, mutant influenza viruses. The mutant viruses disclosed herein include a mutant m2 sequence, and are useful in immunogenic compositions, e.g., as vaccines. Flugen, Inc. |
This present invention relates to compositions and methods for stabilizing a dried vaccine formulations. In particular, the invention provides a method for producing a vaccine composition comprising the steps of providing an aqueous composition comprising a buffer, the vaccine components and between 17.5% w/w and 60% w/w of a non-polymeric sugar, freezing the composition, and applying microwave radiation under a pressure lower than atmospheric pressure in order to sublimate the composition and obtain a dried vaccine formulation. Merck Sharp & Dohme Corp. |
A dual formulation for vaccines against neisseria meningitidis serogroup b (‘men-b’) comprises (i) an oil-in-water emulsion adjuvant and (ii) a men-b immunogenic component in lyophilised form. The lyophilised men-b antigens can be reconstituted into liquid adjuvanted form at the time of use ready for administration to a patient. Glaxosmithkline Biologicals Sa |
A single or multistage mycobacterium avium subsp. paratuberculosis subunit vaccine The present invention provides one or more immunogenic polypeptides for use in a preventive or therapeutic vaccine against latent or active infection in a human or animal caused by a mycobacterium species, e.g. Mycobacterium avium subsp. Janssen Sciences Ireland Uc |
Embodiments are directed to malaria vaccines comprising a bacteriophage vlp displaying a heterologous peptide identified by affinity selection as an anti-malaria mimotope.. . Leidos, Inc. |
Wherein r1 is c1-6alkylamino, c1-6alkoxy, or c3-7cycloalkyloxy; m is an integer having a value of 3 to 6; n is an integer having a value of 0 to 4; and salts thereof are inducers of human interferon. Compounds which induce human interferon may be useful in the treatment of various disorders, for example the treatment of allergic diseases and other inflammatory conditions for example allergic rhinitis and asthma, the treatment of infectious diseases and cancer, and may also be useful as vaccine adjuvants.. |
Dry formulations of vaccines that are room temperature stable The present invention discloses dry formulations of room temperature stable vaccines that comprise a live attenuated virus, a sugar stabilizer, and an amino acid stabilizer. The present invention also discloses the manufacture of such vaccines and methods of protecting an animal by administration of such vaccines.. Intervet Inc. |
Fixation of vaccine formulations on devices for epidermal immunisation by oily adjuvants The present patent application relates to a pharmaceutical product and a device for the storage, handling, transport and administration of active ingredients, pharmaceutical formulations and vaccines. In addition, the present invention relates to a device and pharmaceutical product suitable for intra-dermal, intra-mucosal or epidermal administration like for example intra-dermal or epidermal immunisation. Lts Lohmann Therapie-systeme Ag |
Compositions containing amino acids, phosphate and manganese and their uses The invention provides methods of producing vaccines directed against microorganisms, with the methods comprising culturing, harvesting and/or suspending the microorganism in the presence of a radiation-protective composition and irradiating the bacteria or viruses with a dose of radiation sufficient to render the microorganism replication-deficient and/or non-infective. The radiation-protective compositions used in the methods of the present invention comprise at least one nucleoside, at least one antioxidant and at least one small peptide. The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc. |
Compounds and methods for diagnosis and immunotherapy of tuberculosis Compounds and methods for diagnosing tuberculosis or for inducing protective immunity against tuberculosis are disclosed. The compounds provided include polypeptides that contain at least one immunogenic portion of one or more mycobacterium proteins and dna molecules encoding such polypeptides. Corixa Corpoation |
Order a batch download of a huge number of patent PDFs.
Bulk PDF Downloads
This is a premium service.
|
Boosting the efficacy of dna-based vaccines with non-thermal dbd plasma The efficacy of a dna-based vaccine in terms of eliciting a desired immune response is enhanced by directing a non-thermal plasma generated by a non-thermal plasma generator at the site on the patient's skin where the vaccine was previously introduced.. . Ep Technologies Llc |
Compositions of vaccines and adjuvants and methods for the treatment of urinary tract infections This invention describes novel adjuvant compositions and formulations with excellent stability at refrigerated and room temperatures and up to and about 37° c. That can be produced at remarkably low costs. Sequoia Sciences, Inc |
Gb1 peptidic compounds that specifically bind to a hemagglutinin target protein, and libraries that include the same, as well as methods of making and using the same, are provided. Also provided are methods and compositions for making and using the compounds. The Governing Council Of The University Of Toronto |
The present invention encompasses fmdv vaccines or compositions. The vaccine or composition may be a vaccine or composition containing fmdv antigens. Merial, Inc. |
The present invention relates to lyme disease vaccines, in particular to vaccines including one or more isolated polypeptides of borrelia burgdorferi ss, borrelia afzelii or borrelia garinii.. . Centre National De La Recherche Scientifique - Cnrs |
Formulations and methods are provided for stabilizing antigens in dry solid vaccines. One aspect relates to dry solid formulations of influenza vaccines including one or more excipients identified as imparting stability to influenza antigens. Georgia Tech Research Corporation |
Serum antibody assay for determining protection from malaria, and pre-erythrocytic subunit vaccines Disclosed herein are diagnostic assays for identifying individuals that are protected against plasmodium falciparum caused malaria. Such assays are particularly useful for determining not only the protective efficacy of pf whole parasite vaccines for individual subjects, but also within populations of vaccinated subjects. The United States Of America,as Represented By The Secretary, Department Of Health And Human Service |
The present invention provides four purified preparation containing a polynucleic acid molecule encoding porcine torque teno virus (pttv) genotypes or subtypes pttv1a-va, pttv1b-va, pttv2b-va, and pttv2c-va. The present invention also provides infectious dna clones, biologically functional plasmid or viral vector containing the infectious nucleic acid genome molecule of the same. Virginia Tech Intellectual Properties, Inc. |
Human immune therapies using a cd27 agonist alone or in combination with other immune modulators Methods of inducing t cell proliferation and expansion in vivo for treating conditions wherein antigen-specific t cell immune response are therapeutically desirable such as cancer, infection, inflammation, allergy and autoimmunity and for enhancing the efficacy of vaccines are provided. These methods comprise the administration of at least one cd27 agonist, preferably an agonistic cd27 antibody, alone or in association with another moiety such as immune stimulant or immune modulator such as an anti-cd40, ox-40, 4-1bb, or ctla-4 antibody or an agent that depletes regulatory cells, or a cytokine. University Of Southampton |
The present invention provides monoclonal antibodies, or antigen-binding fragments thereof, that bind to ebola virus glycoproteins, pharmaceutical compositions comprising the antibodies and methods of use. The antibodies of the invention are useful for inhibiting or neutralizing ebola virus activity, thus providing a means of treating or preventing ebola virus infection in humans. Regeneron Pharmaceuticals, Inc. |
The present invention is related to a fusion protein comprising a variant of a nucleoprotein antigen from influenza strain a, b or c, and a variant of a c4bp oligomerization domain for increasing the cellular immunogenicity of the nucleoprotein antigen from influenza. The invention is also related to nucleic acids, vectors, fusion proteins and immunogenic compositions, for their use as a vaccine or immunotherapy for the prevention and treatment of influenza disease.. Imaxio |
Immunogenic compositions relating to dna launched suicidal flaviviruses and methods of administering the same are described herein.. . Chontech Pharma Ab |
The present invention relates to immunological compositions and vaccines that target diseases caused by infection with streptococcus pyogenes. In particular, the compositions of the present invention find use in therapeutic and/or prophylactic methods for the treatment or prevention of morbidity associated with infection with streptococcus pyogenes. Vaxform Llc |
Provided herein are monocot seed compositions and methods of making a monocot seed product expressing high levels of recombinant osp fusion protein. In some embodiments, a rice seed composition is used in the manufacture of a lyme disease vaccine formulation. Ventria Bioscience, Inc. |
Disclosed are composite cancer vaccines, in one embodiment generated through 3-dimensional bioprinting or through inoculation of roller cultures. The utilization of decellularized biological matrices such as placental tissue or subintestinal submucosal tissue is disclosed as a substrate for 3-dimensional tissue culture. Batu Biologics, Inc. |
The present disclosure is directed to vaccines, antibodies, and/or immunogenic conjugate compositions targeting the ssea3/ssea4/globoh associated epitopes (natural and modified) which elicit antibodies and/or binding fragment production useful for modulating the globo-series glycosphingolipid synthesis. The present disclosure relates to methods and compositions which can modulate the globo-series glycosphingolipid synthesis. Academia Sinica |
Carbon nanotube (cnt)-based compositions for activating cellular immune responses are provided. The cnts function as high surface area scaffolds for the attachment of t cell ligands and/or antigens. Yale University |
The invention provides a composition useful to prepare high titer influenza viruses, e.g., in the absence of helper virus, which includes at least five internal genes from an influenza virus isolate that replicates to high titers in embryonated chicken eggs or mdck cells.. . Wisconsin Alumni Research Foundation (warf) |
Described herein is a soluble hiv-1 retrovirus transmembrane glycoprotein gp41 trimer (soc-gp41m-fd) containing a partial ectodomain and the cytoplasmic domain, that is fused to the small outer capsid (soc) protein of bacteriophage t4 and the foldon domain of the bacteriophage t4 fibritin (fd). The gp41 trimer that has a prehairpin structure could be utilized to understand the mechanism of viral entry and as a candidate for development of hiv-1 vaccines, diagnostics and therapeutics. The Catholic University Of America |
The present invention provides a dried influenza vaccine preparation in which the activity of an influenza vaccine antigen can be stably maintained even when stored without strictly maintaining a low temperature, and which can be stably supplied. The present invention also provides a method of producing the dried influenza vaccine preparation. Nitto Denko Corporation |
Disclosed are compositions and methods related to recombinant arenaviruses and their use in vaccines for the treatment or prevention of an arenavirus infection.. . University Of Rochester |
Disclosed are stable conjugate vaccine formulations for protection against salmonella typhi, and methods of conjugation between vi-polysaccharide of s. Typhi to tetanus toxoid as the carrier protein, responsible for producing improved t-dependent immune response against typhoid fever caused by salmonella typhi. Bharat Botech International Limited |
The present invention discloses novel isolates of neorickettsia risticii, compositions comprising such isolates, vaccines and methods for using such vaccines against potomac horse fever.. . Intervet Inc. |
Compositions comprising angiogenic factors and methods of use thereof The present invention provides recombinant listeria strains comprising an angiogenic factor, recombinant polypeptides comprising an angiogenic factor operatively linked to a polypeptide comprising a pest-like sequence, recombinant nucleotide molecules encoding same, related vaccines, and immunogenic and therapeutic methods utilizing same.. . The Trustees Of The University Of Pennsylvania |
Specific multivalent virus-like particle vaccines and uses thereof The invention provides a vlp free of a viral genome comprising two or more display polypeptides, nucleic acid molecules, polymers of the nucleic acid, lipopolysaccharides, lipopeptides, peptidoglycans and/or small molecules.. . The Board Of Trustees Of The Leland Standford Junior University |
Follow us on Twitter
@FreshPatents###
This listing is a sample listing of patent applications related to Vaccine for is only meant as a recent sample of applications filed, not a comprehensive history. There may be associated servicemarks and trademarks related to these patents. Please check with patent attorney if you need further assistance or plan to use for business purposes. This patent data is also published to the public by the USPTO and available for free on their website. Note that there may be alternative spellings for Vaccine with additional patents listed. Browse our RSS directory or Search for other possible listings.